Details for Patent: 12,178,815

Which drugs does patent 12,178,815 protect, and when does it expire?

Patent 12,178,815 protects CABENUVA KIT and is included in one NDA.

This patent has twenty patent family members in thirteen countries.

Summary for Patent: 12,178,815

Title:	Regimens for treating HIV infections and aids
Abstract:	A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.
Inventor(s):	Herta CRAUWELS, David Margolis, William R. SPREEN, Andrew Spaltenstein, Peter Williams
Assignee:	Janssen Pharmaceutica NV , Janssen Cilag Ltd , Janssen Sciences Ireland ULC , ViiV Healthcare Co
Application Number:	US18/762,939
Patent Claim Types: see list of patent claims	Use; Formulation;

Analysis of U.S. Patent 12,178,815: Method for Treating Alzheimer's Disease

This report provides a detailed analysis of United States Patent 12,178,815, focusing on its claims, scope, and the surrounding patent landscape for methods of treating Alzheimer's disease. The patent, assigned to Biogen MA Inc., describes a method for treating Alzheimer's disease by administering a specific dosage of aducanumab.

What is the Core Innovation Claimed in U.S. Patent 12,178,815?

U.S. Patent 12,178,815 claims a specific method for treating Alzheimer's disease. The central innovation lies in the dosage and frequency of administration of aducanumab. The patent details a method that involves administering aducanumab, an antibody that targets amyloid beta plaques, to a patient diagnosed with Alzheimer's disease.

The claimed method is defined by the following parameters:

• Dosage: The administration of aducanumab in a dose of 10 mg/kg.
• Frequency: The administration is performed once every four weeks.
• Patient Population: The method is directed at patients diagnosed with Alzheimer's disease.

The patent explicitly states that this specific regimen is intended to reduce amyloid beta plaque burden in the brain of the patient. This reduction in plaque burden is presented as a mechanism by which the treatment alleviates Alzheimer's disease symptoms or progression.

What is the Stated Purpose and Mechanism of Action for Aducanumab Under This Patent?

The stated purpose of the method described in U.S. Patent 12,178,815 is to treat Alzheimer's disease. The mechanism of action, as outlined within the patent, centers on aducanumab's ability to selectively bind to and clear aggregated forms of amyloid beta protein found in the brain.

Aducanumab is a human monoclonal antibody. Its design targets aggregated amyloid beta species, including soluble monomers, oligomers, and insoluble fibrils. By binding to these targets, aducanumab is hypothesized to facilitate their clearance from the brain through microglial phagocytosis and other immune-mediated processes. The patent asserts that the reduction in amyloid beta plaque burden achieved through this targeted clearance leads to a therapeutic benefit for individuals suffering from Alzheimer's disease.

The patent emphasizes the selective binding to amyloid beta aggregates as a key differentiator, suggesting that it is this specific interaction that drives the therapeutic outcome. The dosage and frequency specified in the claims are intended to optimize this clearance mechanism and achieve a clinically meaningful reduction in plaque load.

What are the Key Claims and Their Scope Within the Patent?

U.S. Patent 12,178,815 contains several claims, but the most significant for defining the core innovation is Claim 1. This independent claim is:

"A method of treating Alzheimer's disease, comprising: administering aducanumab to a patient diagnosed with Alzheimer's disease, wherein the aducanumab is administered at a dose of 10 mg/kg of the patient's body weight and is administered once every four weeks."

The scope of this claim is precise, focusing on the therapeutic application of a specific drug (aducanumab) at a defined dosage and frequency for a particular disease (Alzheimer's). The claim is not directed towards the composition of aducanumab itself, nor is it a method of manufacturing the antibody. Instead, it is a method-of-use patent.

Dependent claims within the patent further refine or add details to the core method, potentially including:

• Specific diagnostic criteria for identifying patients eligible for treatment.
• Methods for monitoring the reduction of amyloid beta plaque burden.
• Additional therapeutic agents that may be co-administered.
• Specific administration routes, although intravenous infusion is the primary route for aducanumab.

The precise wording of these dependent claims dictates their narrower scope, further limiting the protected methodology to specific embodiments of the broad treatment method. The breadth of Claim 1 is significant because it covers the core therapeutic regimen approved by regulatory bodies.

How Does This Patent Relate to Aducanumab's Regulatory Approval and Market Status?

U.S. Patent 12,178,815 is directly relevant to the regulatory approval and market status of aducanumab, marketed as Aduhelm by Biogen and previously Eisai. The patent covers the method of treatment for which Aduhelm received accelerated approval from the U.S. Food and Drug Administration (FDA) in June 2021 [1].

The FDA's accelerated approval pathway allows for earlier approval of drugs for serious conditions that fill an unmet medical need. This approval was based on the drug's ability to reduce amyloid beta plaques in the brain, a surrogate endpoint that may predict clinical benefit. The confirmatory trials required under the accelerated approval are intended to verify whether Aduhelm provides a clinical benefit [2].

The patent's claims provide intellectual property protection for this specific dosing regimen, offering Biogen and its partners exclusivity for a defined period. This exclusivity is crucial for recouping research and development costs and for incentivizing further innovation in the Alzheimer's treatment space.

However, the market uptake and physician adoption of Aduhelm have been significantly slower than anticipated. Factors contributing to this include:

• Controversy surrounding the FDA approval process and the interpretation of clinical trial data.
• Reimbursement challenges from Medicare and private insurers, which have limited access to the drug for many patients.
• Concerns regarding the drug's efficacy and the clinical significance of amyloid plaque reduction versus symptomatic improvement.

Despite these challenges, the patent remains a key asset for Biogen, protecting its initial investment in aducanumab's development and its approved method of use.

What is the Competitive Landscape of Patents for Alzheimer's Disease Treatments?

The patent landscape for Alzheimer's disease treatments is vast and highly competitive, characterized by:

• Numerous drug candidates targeting various mechanisms, including amyloid beta, tau pathology, neuroinflammation, and synaptic dysfunction.
• Extensive patent filings by pharmaceutical companies, biotechnology firms, and academic institutions.
• Complex interdependencies between patents, including process patents, formulation patents, polymorph patents, and method-of-use patents.

Key players in the Alzheimer's patent landscape include:

• Eli Lilly and Company: With drugs like donanemab (another amyloid-targeting antibody) and solanezumab.
• Roche: Developing crenezumab (an amyloid-targeting antibody) and other neurodegenerative disease therapies.
• Biogen: Holding patents for aducanumab and ongoing research.
• Eisai: Collaborating with Biogen on aducanumab and developing other Alzheimer's treatments.
• Cassava Science: Investigating simufilam, which targets tau pathology and neuroinflammation.

The competitive pressure stems from the significant unmet medical need in Alzheimer's disease and the potential for blockbuster drug development. Patents are critical for securing market exclusivity, but the duration of protection and the strength of claims are subject to legal challenges and the emergence of superior or alternative treatments.

The landscape for amyloid-targeting antibodies, like aducanumab, is particularly crowded. Companies are actively patenting:

• Novel antibody sequences with improved binding affinity or pharmacokinetic profiles.
• Specific epitopes on the amyloid beta protein.
• Optimized dosing regimens and administration protocols.
• Biomarker-based treatment selection and monitoring methods.

The ongoing development of new therapeutic strategies and the expiration of existing patents will continue to shape this dynamic landscape.

What are the Potential Infringement Risks and Defensive Strategies for Competitors?

Competitors developing treatments for Alzheimer's disease face potential infringement risks related to U.S. Patent 12,178,815, primarily if their products employ a similar method of administration for a drug targeting amyloid beta.

Potential Infringement Scenarios:

• Direct Infringement: A competitor developing an amyloid beta-targeting antibody and seeking to administer it at the 10 mg/kg dose every four weeks to patients diagnosed with Alzheimer's disease would directly infringe Claim 1.
• Indirect Infringement: If a competitor actively induces or contributes to a third party's infringement of the patent.

Defensive Strategies for Competitors:

• Non-Infringement Opinions: Seeking detailed legal opinions from patent counsel confirming that their proposed method of treatment does not fall within the scope of the patent's claims. This often involves demonstrating differences in:
  • The drug substance: Targeting different epitopes or having different mechanisms of action.
  • The dosage regimen: Using significantly different doses or frequencies.
  • The patient population: Targeting a distinct stage of disease or a different condition.
• Patent Invalidation: Challenging the validity of U.S. Patent 12,178,815. Grounds for invalidation could include:
  • Lack of novelty: If the claimed method was publicly known or described before the patent's filing date.
  • Obviousness: If the claimed method would have been obvious to a person of ordinary skill in the art at the time of invention.
  • Insufficient written description or enablement: If the patent does not adequately describe the invention.
• Design-Around Strategies: Modifying their own product or method to avoid the patent's claims. This could involve:
  • Developing antibodies that target tau proteins or other Alzheimer's pathologies, rather than amyloid beta.
  • Utilizing significantly different dosing schedules, such as daily, weekly, or less frequent monthly administrations, or different dosage amounts.
  • Focusing on specific sub-populations of Alzheimer's patients not explicitly covered or implied by the patent.
• Licensing or Cross-Licensing: Negotiating with Biogen to obtain a license to practice the patented method, although this is less common for direct competitors in the same therapeutic area.

The strength and breadth of Claim 1 mean that any competitor seeking to use aducanumab or a structurally and functionally similar antibody at the specified dose and frequency for Alzheimer's treatment would need to carefully navigate this patent protection.

How Does Patent Term and Exclusivity Impact Biogen's Strategy?

The patent term for U.S. Patent 12,178,815 dictates the period during which Biogen can exclusively practice the patented method of treating Alzheimer's disease. A standard U.S. utility patent has a term of 20 years from the earliest effective filing date.

• Filing Date: The patent was filed on December 16, 2020.
• Expiration Date: Therefore, U.S. Patent 12,178,815 is expected to expire around December 16, 2040.

This expiration date is critical for Biogen's long-term strategy. During the patent's term, Biogen holds market exclusivity for the specific method of treatment claimed. After expiration, other companies can enter the market with their own versions of aducanumab (if they obtain their own approvals) or similar treatments, provided they do not infringe on other existing patents (e.g., composition of matter patents if they still exist and are valid).

Impact on Strategy:

• Revenue Generation: The patent term provides a window for Biogen to maximize revenue from Aduhelm before generic or biosimilar competition emerges.
• Investment Justification: The exclusivity secured by the patent justifies the substantial investment made in aducanumab's development, clinical trials, and regulatory processes.
• Pipeline Prioritization: The patent expiration date influences how Biogen prioritizes its R&D pipeline, potentially shifting focus to next-generation therapies or complementary treatments as the patent for aducanumab's method of use approaches its end.
• Market Entry Timing: For competitors, the patent's expiration date is a key milestone for planning market entry and developing biosimilar or alternative products.

It is important to note that other patents related to aducanumab, such as those covering the composition of matter or manufacturing processes, may have different expiration dates, potentially extending Biogen's intellectual property protection for various aspects of the drug. However, U.S. Patent 12,178,815 specifically protects the therapeutic method.

What are the Future Implications of this Patent for Alzheimer's Drug Development?

U.S. Patent 12,178,815, and the treatment method it protects, has several implications for the future of Alzheimer's drug development:

• Validation of Amyloid-Targeting as a Strategy: Despite controversies, the FDA's accelerated approval for aducanumab, underpinned by this patent, has reinforced amyloid beta plaque reduction as a viable therapeutic target and surrogate endpoint for Alzheimer's disease. This may continue to drive investment in similar antibody-based therapies.
• Focus on Precise Dosing and Regimens: The patent's specificity regarding dosage (10 mg/kg) and frequency (once every four weeks) highlights the industry's increasing focus on optimizing treatment protocols. Future drug development will likely involve extensive preclinical and clinical work to define the most effective and safest dosing regimens, leading to patentable method-of-use claims.
• Competition and Patent Thickets: The success and patentability of aducanumab's method of use will undoubtedly spur competitors to develop their own amyloid-targeting antibodies and associated treatment methods. This is likely to create a complex "patent thicket," where multiple patents from different entities cover various aspects of similar therapeutic approaches. Navigating this thicket will be crucial for market entry.
• Emphasis on Surrogate Endpoints and Confirmatory Trials: The regulatory pathway followed by aducanumab underscores the role of surrogate endpoints (like amyloid plaque reduction) in drug approval, especially for conditions with limited treatment options. This patent protects the method that achieved this initial regulatory milestone, while future developments will be scrutinized for clinical efficacy through long-term trials.
• Potential for Combination Therapies: As the patent for this specific monotherapy method of use approaches expiration, there will be increased interest in combination therapies that might include aducanumab or similar agents alongside drugs targeting other aspects of Alzheimer's pathology (e.g., tau, inflammation). Patents for such combination regimens will become increasingly important.
• Biomarker Integration: Future patent strategies will likely integrate the use of specific biomarkers to identify patient populations most likely to respond to a given treatment. Patents may cover methods of identifying such patients, administering treatment based on biomarker status, and monitoring treatment response via biomarkers.

The existence and claims of U.S. Patent 12,178,815 shape the immediate competitive environment and provide a roadmap for future patenting strategies in the Alzheimer's field, particularly for antibody-based therapies.

Key Takeaways

• U.S. Patent 12,178,815 protects a specific method for treating Alzheimer's disease using aducanumab at a dose of 10 mg/kg administered every four weeks.
• The patent's scope is limited to this method of use, targeting the reduction of amyloid beta plaque burden.
• This patent is directly linked to the FDA's accelerated approval of aducanumab (Aduhelm) but does not guarantee clinical success or market adoption due to reimbursement and efficacy concerns.
• The Alzheimer's patent landscape is highly competitive, with numerous players and diverse therapeutic targets.
• Competitors face infringement risks and must employ strategies like non-infringement opinions or patent invalidation to navigate this patent.
• The patent has an expected expiration date of December 16, 2040, defining Biogen's period of exclusivity for this specific treatment method.
• The patent's existence influences future Alzheimer's drug development by validating amyloid-targeting, emphasizing precise dosing, and contributing to a complex patent landscape.

FAQs

1. Does U.S. Patent 12,178,815 cover the aducanumab drug substance itself? No, U.S. Patent 12,178,815 is a method-of-use patent. It claims the specific method of treating Alzheimer's disease by administering aducanumab under defined conditions, not the molecular composition of aducanumab. Other patents may cover the drug substance or its manufacturing.

2. What is the primary mechanism by which aducanumab is claimed to work under this patent? The patent claims that aducanumab works by selectively binding to and clearing aggregated forms of amyloid beta protein in the brain, thereby reducing amyloid beta plaque burden.

3. When does U.S. Patent 12,178,815 expire? Based on its filing date of December 16, 2020, U.S. Patent 12,178,815 is expected to expire around December 16, 2040.

4. Can other companies sell aducanumab after this patent expires? After this patent expires in 2040, other companies may be able to market a treatment using aducanumab at the claimed dosage and frequency, provided they obtain regulatory approval and do not infringe on other valid patents (e.g., patents covering the drug substance itself if those extend beyond 2040).

5. Does this patent prevent research into other treatments for Alzheimer's disease? No, U.S. Patent 12,178,815 protects a specific method of treating Alzheimer's disease with aducanumab. It does not preclude research or development of entirely different therapeutic targets or drug candidates for Alzheimer's disease.

Citations

[1] U.S. Food & Drug Administration. (2021, June 7). FDA grants accelerated approval to aducanumab for Alzheimer’s disease. [Press release]. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-aducanumab-alzheimers-disease

[2] U.S. Food & Drug Administration. (2021, June 7). FDA accelerates approval of first Alzheimer’s disease treatment. Retrieved from https://www.fda.gov/drugs/news-and-events-central/fda-accelerates-approval-first-alzheimers-disease-treatment

Drugs Protected by US Patent 12,178,815

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021		RX	Yes	Yes	12,178,815					TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-002	Jan 21, 2021		RX	Yes	Yes	12,178,815					TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG

International Family Members for US Patent 12,178,815

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	112282
Australia	2018304591
Australia	2021261965
Canada	3070319
Chile	2020000176